Vir Biotechnology (VIR) Projected to Post Quarterly Earnings on Monday

Vir Biotechnology (NASDAQ:VIR) is projected to issue its Q4 2025 results after the market closes on Monday, February 23rd. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $19.9050 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, February 23, 2026 at 5:30 PM ET.

Vir Biotechnology Price Performance

Shares of NASDAQ:VIR opened at $7.56 on Friday. The firm has a fifty day moving average price of $6.73 and a two-hundred day moving average price of $5.92. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -2.09 and a beta of 1.69. Vir Biotechnology has a one year low of $4.16 and a one year high of $9.93.

Analysts Set New Price Targets

VIR has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. Barclays set a $26.00 price target on Vir Biotechnology in a research report on Tuesday. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Vir Biotechnology in a research report on Tuesday, December 30th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $14.00 target price on shares of Vir Biotechnology in a research report on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Vir Biotechnology has an average rating of “Moderate Buy” and an average price target of $16.29.

Insider Buying and Selling

In related news, Director Vicki L. Sato sold 22,000 shares of Vir Biotechnology stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $7.71, for a total value of $169,620.00. Following the transaction, the director owned 1,144,391 shares in the company, valued at $8,823,254.61. This trade represents a 1.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Endurance (Cayman) Ltd Svf sold 235,971 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $6.38, for a total transaction of $1,505,494.98. Following the completion of the sale, the insider directly owned 14,110,209 shares of the company’s stock, valued at $90,023,133.42. This represents a 1.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 912,589 shares of company stock worth $5,711,308 over the last quarter. Company insiders own 16.00% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. AQR Capital Management LLC grew its position in Vir Biotechnology by 2,088.4% during the 1st quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock worth $1,739,000 after acquiring an additional 256,037 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Vir Biotechnology during the first quarter valued at approximately $359,000. Goldman Sachs Group Inc. grew its holdings in shares of Vir Biotechnology by 43.6% in the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock worth $4,813,000 after purchasing an additional 225,544 shares during the last quarter. Woodline Partners LP grew its holdings in shares of Vir Biotechnology by 245.6% in the first quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock worth $3,024,000 after purchasing an additional 331,701 shares during the last quarter. Finally, Focus Partners Wealth increased its stake in shares of Vir Biotechnology by 15.3% in the first quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock worth $125,000 after buying an additional 2,566 shares during the period. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.